anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

223,621-223,680 of 319,975

filter-aware
01
Slide 1
The slide uses Python-like code snippets as a design element to emphasize the computational nature of their drug discovery process.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations 1 hit
02
Absci | Investor Presentation Deck | 42 slidesAbsci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations 1 hit
03
Uses a rhetorical question to frame the company's value proposition.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations Beat · HookLoop · Golden Circle1 hit
04
Uses a process diagram to show the 'loop' of optimization (affinity, developability, toxicity) leading to suboptimal outcomes.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
05
Uses a visual comparison between small molecule data availability and biologic data scarcity.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations Beat · Why nowLoop · Cost Of Inaction1 hit
06
The slide uses a process flow diagram to contrast traditional/public data with the high-volume output of the ACE Assay.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
07
The slide uses a high-contrast metaphor to frame the company's value proposition. The background includes a faint, real-world lab setting with a process diagram on a whiteboard.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
08
The slide uses a flywheel diagram to illustrate the iterative nature of their drug creation process.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
09
The diagram shows a circular process flow between lab work and AI model training.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
10
The slide uses a circular process flow to represent a data-driven feedback loop.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
11
The slide uses a flywheel/loop framework to show the iterative nature of their platform.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
12
The flywheel diagram is a central visual component representing the core operational advantage.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations Beat · Evidence1 hit
13
The slide uses QR codes to link to specific research papers.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations Beat · Evidence1 hit
14
The slide uses a process flow framework to visualize the end-to-end drug development pipeline.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations Beat · Evidence1 hit
15
The slide uses a process flow framework to explain the technical solution.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations Beat · Evidence1 hit
16
The slide uses a process flow diagram to explain the technical methodology.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations Beat · Evidence1 hit
17
The slide uses a split-screen layout to contrast the initial goals of the case study with the achieved outcomes.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations Beat · Evidence1 hit
18
The slide uses a dot plot to show search space diversity and a bar chart to compare binding rates against various baselines.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations Beat · Evidence1 hit
19
The slide demonstrates that Variant A* shows higher potency than the wild-type trastuzumab in both binding and ADCC assays.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations Beat · Evidence1 hit
20
The slide uses a Gantt chart to illustrate the overlapping timelines of two batches of development.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations Beat · Roadmap1 hit
21
The slide uses a process flow framework to show the progression from target discovery to optimized antibodies.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations Beat · Traction1 hit
22
The flywheel framework is explicitly labeled. The right side details the wet lab validation process.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations Beat · Traction1 hit
23
The slide highlights the challenge of binding affinity (Kd) for the beta variant (607 nM) compared to others, using molecular visualization of RBD mutations.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations Beat · Traction1 hit
24
The slide uses a process diagram to explain the technical methodology of Absci's drug discovery platform.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations Beat · Traction1 hit
25
The slide uses a process flow (1: Data generation, 2: Model training) followed by validation results (scatter plot and correlation table).Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations Beat · Traction1 hit
26
SPR stands for Surface Plasmon Resonance, a standard technique for measuring binding affinity.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations Beat · Traction1 hit
27
The slide uses a process diagram to explain the AI workflow and a table to show quantitative improvements in binding affinity (nM KD) for five different antibody candidates.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations Beat · Traction1 hit
28
The slide uses a consistent visual metaphor of a central antibody binding to three distinct targets in each of the three columns.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
29
The slide uses a histogram to visualize the distribution of binding affinity (-log10(Kd)) for designed variants versus the wild-type baseline.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
30
The slide uses a hub-and-spoke visual metaphor to show a single antibody binding to multiple targets (human/mouse/cyno, isoforms, or viral variants).Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
31
The slide uses a process flow diagram to explain the core technology platform.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
32
The slide highlights the integration of AI in the discovery process and lists key clinical partners.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations 1 hit
33
Includes a Kaplan-Meier survival curve as evidence for the clinical relevance of TLS.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations 1 hit
34
The slide uses a split-screen layout to contrast two service offerings.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations Beat · Go-to-market1 hit
35
Absci | Investor Presentation Deck | 42 slidesAbsci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations Beat · Go-to-market1 hit
36
The slide uses a grid layout to present four distinct partnership case studies with testimonials.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations Beat · Go-to-market1 hit
37
Uses a comparative timeline to illustrate process efficiency gains.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations Beat · Timeline1 hit
38
The slide uses a before-after framing to demonstrate competitive advantage in speed and cost.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations 1 hit
39
The chart uses a grouped bar chart to illustrate the economic structure across five categories: Research Funding/Cost, Upfront Payment, Clinical Milestones, Commercial Milestones, and Royalties.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations 1 hit
40
Includes a dog as 'Chief Morale Officer', a common startup culture trope.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations 1 hit
41
Slide highlights organizational maturity and human capital.Absci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations 1 hit
42
Absci | Investor Presentation Deck | 42 slidesAbsci | Investor Presentation Deck | 42 slides · Absci
Pitch deck Investor relations 1 hit
01
Slide 1
Includes branding for argenx and the ADDRESS study.argenx SE | Investor Presentation Deck | 9 slides · argenx
Conference presentation Investor relations Beat · Attention1 hit
02
argenx SE | Investor Presentation Deck | 9 slidesargenx SE | Investor Presentation Deck | 9 slides · argenx
Conference presentation Investor relations 1 hit
22
The table includes footnotes explaining specific line items like sales tax liability, transaction costs, and various fair value adjustments.Vivid Seats | Results Presentation Deck | 22 slides · Vivid Seats
Conference presentation Investor relations 1 hit
01
Slide 1
The slide displays seven distinct brand logos/images: Perfect Diary, Little Ondine, Pink Bear, Dr. Wu, Galénic, Eve Lom, and Abby's Choice.Yatsen | Results Presentation Deck | 15 slides · Yatsen
Conference presentation Investor relations 1 hit
02
Yatsen | Results Presentation Deck | 15 slidesYatsen | Results Presentation Deck | 15 slides · Yatsen
Conference presentation Investor relations 1 hit
03
Yatsen | Results Presentation Deck | 15 slidesYatsen | Results Presentation Deck | 15 slides · Yatsen
Conference presentation Investor relations Beat · Attention1 hit
04
Includes a footnote regarding the date of the cash position.Yatsen | Results Presentation Deck | 15 slides · Yatsen
Conference presentation Investor relations Beat · AttentionLoop · Hypothesis Test1 hit
05
Data sourced from China National Bureau of Statistics (CNBS).Yatsen | Results Presentation Deck | 15 slides · Yatsen
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
06
Yatsen | Results Presentation Deck | 15 slidesYatsen | Results Presentation Deck | 15 slides · Yatsen
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
07
The slide highlights a shift in revenue mix towards skincare brands despite a slight YoY decline in absolute revenue.Yatsen | Results Presentation Deck | 15 slides · Yatsen
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
08
1 DR.WU's mainland China businessYatsen | Results Presentation Deck | 15 slides · Yatsen
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
09
The chart highlights a significant reduction in store count, specifically noting that adjustments were mostly completed in 2022.Yatsen | Results Presentation Deck | 15 slides · Yatsen
Conference presentation Investor relations Beat · Satisfaction1 hit
10
Yatsen | Results Presentation Deck | 15 slidesYatsen | Results Presentation Deck | 15 slides · Yatsen
Conference presentation Investor relations Beat · Action1 hit
11
Slide 11 of a presentation deck.Yatsen | Results Presentation Deck | 15 slides · Yatsen
Conference presentation Investor relations Beat · Action1 hit
12
The chart shows a 3.8 percentage point YoY increase in total operating expenses.Yatsen | Results Presentation Deck | 15 slides · Yatsen
Conference presentation Investor relations Beat · Action1 hit
13
The slide provides a detailed breakdown of adjustments made to GAAP figures to arrive at non-GAAP metrics.Yatsen | Results Presentation Deck | 15 slides · Yatsen
Conference presentation Investor relations Beat · Action1 hit
14
The chart displays two distinct metrics: a running balance of cash/investments (top row of ovals) and quarterly operating cashflow (bars).Yatsen | Results Presentation Deck | 15 slides · Yatsen
Conference presentation Investor relations Beat · Action1 hit
15
Yatsen | Results Presentation Deck | 15 slidesYatsen | Results Presentation Deck | 15 slides · Yatsen
Conference presentation Investor relations Beat · Action1 hit